Sales start for Otivio AS and Innokas Medical’s FlowOx 2.0 device

FlowOx 2.0, developed in co-creation between Norwegian company Otivio AS and Innokas Medical, has now reached a significant milestone as the device has received CE mark and the sales has started. The first 100 FlowOx 2.0 devices have already been shipped from Innokas’ Kempele factory.

Innokas Medical has been a partner in a consortium led by Norwegian company Otivio AS, to develop the next version of FlowOxTM. It is a clinically promising, patented and cost-efficient home treatment solution for Peripheral Arterial Disease (PAD). The market potential for FlowOx is extremely high as peripheral arterial disease affects more than 200 million people globally, and the patient population is increasing at a rate of 20% per annum due to an aging population, smoking and epidemic growth of diabetes. The global costs of treating PAD amount to $210-380 billion annually.

“It’s been an honor for Innokas to be part of the team developing the next version of FlowOx. Through this innovation, we can contribute to improving healthcare all over the world and the quality of daily life of millions of people,” said Antti Virtanen, Head of PMO at Innokas Medical.

Peripheral Artery Disease is caused by the deposition of fatty material on the inner walls of peripheral arteries, reducing perfusion and nutrition to the muscles and skin. The non-invasive FlowOxTM system is based on negative pulsating pressure therapy, and patient testing has documented that it increases blood flow, reduces pain and heals wound in patient’s feet and legs, in order to prevent amputations and increase life quality.

Co-operation across borders

The co-creation of the next version of FlowOxTM begun already in 2016 when the consortium created by Otivio was granted over 2M€ EU funding. The consortium consisted of partners from Norway, Finland and the UK. After about two years of design and development work, Otivio’s FlowOx 2.0 device received a CE mark in the end of 2018 and today the mass manufacturing of the device has started in Innokas’ Kempele factory. Innokas is also taking care of the after sales support, as well as the needed design and development support of the device.

Read more information here. 

Contact person

Elina Rautiola
Head of Marketing and Communications

Source: Innokas Medical